Share
News
1 - 2 of 2 news items
-
06 June 2007 /Side effects and trials
The Danish Medicines Agency monitors adverse reactions
During the first two years of a medicinal product's life on the market, adverse reactions are monitored closely. Doctors must report adverse reactions.
-
08 February 2007 /Side effects and trials
New recommendations on the use of MRI contrast agents in patients with impaired renal function
The CHMP-Pharmacovigilance Working Party has considered the safety of gadolinium-containing MRI contrast agents. The Committee has concluded that the recommendations on the use of these contrast agents should be amended for patients with impaired renal function.
